Skip to main content
Fig. 2 | Antimicrobial Resistance & Infection Control

Fig. 2

From: Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

Fig. 2

Ceftolozane/tazobactam vs. piperacillin/tazobactam: influence of variables on ICER (cost per discounted QALY). ICER = Incremental cost-effectiveness ratio; QALY = Quality Adjusted Life Year

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us